Updated Data from Eledon Pharmaceuticals鈥� Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
Eledon Pharmaceuticals (NASDAQ: ELDN) announced upcoming presentations of updated clinical data from its ongoing Phase 1b study of tegoprubart in kidney transplant patients at the World Transplant Congress 2025. The oral presentation, scheduled for August 6, 2025, will feature results from approximately 30 kidney transplant recipients.
The company will also host a satellite symposium on August 3 discussing kidney transplant success metrics, featuring prominent medical faculty. Additionally, new preclinical data on tegoprubart's use in liver transplantation in non-human primates will be presented in a poster session.
Eledon Pharmaceuticals (NASDAQ: ELDN) ha annunciato la presentazione di dati clinici aggiornati dal suo studio di Fase 1b in corso su tegoprubart in pazienti con trapianto renale, durante il World Transplant Congress 2025. La presentazione orale, prevista per il 6 agosto 2025, mostrer脿 i risultati di circa 30 riceventi di trapianto renale.
La societ脿 organizzer脿 inoltre un simposio satellite il 3 agosto dedicato ai parametri di successo nel trapianto renale, con la partecipazione di importanti esperti medici. Saranno inoltre presentati nuovi dati preclinici sull'uso di tegoprubart nel trapianto di fegato in primati non umani, durante una sessione poster.
Eledon Pharmaceuticals (NASDAQ: ELDN) anunci贸 presentaciones pr贸ximas con datos cl铆nicos actualizados de su estudio en curso de Fase 1b sobre tegoprubart en pacientes con trasplante renal en el Congreso Mundial de Trasplantes 2025. La presentaci贸n oral, programada para el 6 de agosto de 2025, incluir谩 resultados de aproximadamente 30 receptores de trasplante renal.
La compa帽铆a tambi茅n organizar谩 un simposio sat茅lite el 3 de agosto para discutir m茅tricas de 茅xito en trasplantes renales, con destacados expertos m茅dicos. Adem谩s, se presentar谩n nuevos datos precl铆nicos sobre el uso de tegoprubart en trasplantes de h铆gado en primates no humanos en una sesi贸n de p贸ster.
Eledon Pharmaceuticals (NASDAQ: ELDN)電� 2025雲� 靹戈硠 鞚挫嫕 旎犯霠堨姢鞐愳劀 歆勴枆 欷戩澑 1b靸� 鞐瓣惮鞚� 鞁犾灔 鞚挫嫕 頇橃瀽 雽�靸� tegoprubart 鞛勳儊 雿办澊韯� 鞐呺嵃鞚错姼毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 甑憪 氚滍憸電� 2025雲� 8鞗� 6鞚�鞐� 鞓堨爼霅橃柎 鞛堨溂氅�, 鞎� 30氇呾潣 鞁犾灔 鞚挫嫕 靾橅槣鞛� 瓴瓣臣毳� 韽暔頃╇媹雼�.
須岇偓電� 霕愴暅 8鞗� 3鞚检棎 鞁犾灔 鞚挫嫕 靹标车 歆�響滊ゼ 欤检牅搿� 頃橂姅 鞙勳劚 鞁彫歆�鞐勳潉 臧滌禍頃橂┌, 鞝�氇呿暅 鞚橂歆勳澊 彀胳棳頃╇媹雼�. 於旉皜搿�, 牍勳澑臧� 鞓侅灔毳橂ゼ 雽�靸侅溂搿� 頃� 臧� 鞚挫嫕鞐愳劀鞚� tegoprubart 靷毄鞐� 甏�頃� 靸堧鞖� 鞝勳瀯靸� 雿办澊韯瓣皜 韽姢韯� 靹胳厴鞐愳劀 氚滍憸霅� 鞓堨爼鞛呺媹雼�.
Eledon Pharmaceuticals (NASDAQ : ELDN) a annonc茅 des pr茅sentations 脿 venir de donn茅es cliniques mises 脿 jour issues de son 茅tude de phase 1b en cours sur tegoprubart chez des patients transplant茅s r茅naux lors du World Transplant Congress 2025. La pr茅sentation orale, pr茅vue le 6 ao没t 2025, pr茅sentera les r茅sultats d'environ 30 receveurs de greffe r茅nale.
L'entreprise organisera 茅galement un symposium satellite le 3 ao没t, abordant les crit猫res de succ猫s en transplantation r茅nale, avec la participation de professeurs m茅dicaux renomm茅s. De plus, de nouvelles donn茅es pr茅cliniques sur l'utilisation de tegoprubart dans la transplantation h茅patique chez des primates non humains seront pr茅sent茅es lors d'une session poster.
Eledon Pharmaceuticals (NASDAQ: ELDN) k眉ndigte die bevorstehenden Pr盲sentationen aktualisierter klinischer Daten aus seiner laufenden Phase-1b-Studie zu tegoprubart bei Nierentransplantatpatienten auf dem World Transplant Congress 2025 an. Die m眉ndliche Pr盲sentation, geplant f眉r den 6. August 2025, wird Ergebnisse von etwa 30 Nierentransplantatempf盲ngern vorstellen.
Das Unternehmen wird au脽erdem am 3. August ein Satellitensymposium veranstalten, das Erfolgsmetriken bei Nierentransplantationen diskutiert und prominente medizinische Fachkr盲fte einbezieht. Zus盲tzlich werden neue pr盲klinische Daten zur Anwendung von tegoprubart bei Lebertransplantationen an nicht-menschlichen Primaten in einer Postersitzung pr盲sentiert.
- None.
- None.
Insights
Eledon's tegoprubart kidney transplant data presentation represents progress but lacks definitive efficacy or safety results to impact stock significantly.
This announcement highlights Eledon's continued progress with tegoprubart, an anti-CD40L antibody being developed for kidney transplant rejection prevention. The upcoming presentation at the World Transplant Congress will feature updated data from approximately 30 kidney transplant recipients in their ongoing Phase 1b study.
The selection for an oral presentation at a major transplant conference suggests the data warrants attention from the transplant community. However, investors should recognize this remains an early-stage (Phase 1b) trial primarily focused on safety and preliminary efficacy signals rather than definitive outcomes.
CD40L (CD154) is a well-established therapeutic target for transplantation, with several companies pursuing similar approaches. The mechanism works by blocking co-stimulatory signals needed for T-cell activation, potentially offering a more targeted approach than conventional immunosuppressants.
The additional preclinical data in non-human primates for liver transplantation indicates Eledon is exploring expanded applications for tegoprubart beyond kidney transplantation, potentially broadening its market opportunity if successful.
The company's sponsored symposium discussing what defines transplant success suggests they're positioning tegoprubart in the context of long-term outcomes versus short-term rejection prevention, potentially differentiating their approach from competitors. This strategic framing could help establish tegoprubart's value proposition if the data eventually supports claims of improved long-term graft function.
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (鈥淓ledon鈥�) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress聽(WTC) taking place in聽San Francisco聽from聽August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be presented by Dr. John Gill from the University of British Columbia.
Details of the oral presentation are as follows:
Title:聽Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study
Session:聽Oral Presentation, Kidney Novel Immunosuppressant Strategies
Presenter:聽John Gill, MD, MS, University of British Columbia, Vancouver, Canada
Session Date and Time:聽Wednesday, August 6,聽2025: 10:00 a.m. 鈥� 11:15 a.m. PT
Following the session, a copy of the presentation can be found on the Investor section of the Company鈥檚 website at聽.
The Company will also sponsor a satellite symposium at WTC titled: 鈥淲hat Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?鈥�, to be held on聽Sunday, August 3, at聽1:00 pm PT. Faculty include聽Allan Kirk, MD,聽Duke University School of Medicine,聽Oriol Bestard, MD, PhD, MD,聽Vall d鈥橦ebron University Hospital,聽John Gill, MD, MS, University of British Columbia, Alexandre Loupy, MD, PhD, Necker Hospital and聽Deirdre Sawinski, MD,聽Weill Cornell Medical College.
In addition to the oral presentation, new preclinical data, utilizing tegoprubart for the prevention of rejection in non-human primates undergoing liver transplantation, will be presented by Dr. Andrew Adams in a poster session:
Title: Anti-CD154 Facilitates Long-Term Liver Allograft Survival in Non-Human Primates
Session: Poster Presentation
Presenter: Andrew Adams, MD, PhD, University of Minnesota
Date and Time: Sunday, August 3, 2025, 3:30 p.m. PT
About聽Eledon Pharmaceuticals聽and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company鈥檚 lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company鈥檚 website at .
Follow聽Eledon Pharmaceuticals聽on social media:聽;听
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
Source:聽Eledon Pharmaceuticals
FAQ
When will Eledon Pharmaceuticals (ELDN) present its tegoprubart kidney transplant data at WTC 2025?
What will be presented in Eledon's (ELDN) kidney transplant trial update at WTC 2025?
Where can investors find Eledon's (ELDN) WTC 2025 presentation materials?
What additional research will Eledon (ELDN) present at WTC 2025?
